UK Weight Loss Jab Safety: MHRA Reports 216 Suspected Deaths and 18,000 Serious Reactions Linked to GLP-1 Drugs

Weight loss medications such as Mounjaro, Wegovy, Ozempic, and Saxenda have transformed obesity treatment across the UK. Millions of prescriptions have been issued, helping many people lose significant amounts of weight while improving conditions such as type 2 diabetes and cardiovascular risk.

However, newly analyzed UK safety data has raised fresh questions about the risks associated with these medicines.

According to reports submitted to the UK's Medicines and Healthcare products Regulatory Agency (MHRA), there have been 216 suspected deaths and approximately 18,000 serious or fatal adverse reaction reports linked to GLP-1 receptor agonists used for weight loss and diabetes treatment.

While these figures may appear alarming, health experts emphasize that the reports do not prove the medicines directly caused these outcomes. Instead, they represent suspected adverse events reported through the UK's Yellow Card monitoring system.

What the Latest MHRA Data Shows

Analysis of MHRA Yellow Card reports indicates:

• 216 suspected deaths linked to GLP-1 medications
• Around 18,000 serious or fatal suspected adverse reactions
• More than 150,000 total adverse reaction reports since monitoring began
• A reported increase in annual deaths from 22 in 2024 to 94 in 2025

Among the reported fatalities:

• Tirzepatide (Mounjaro): 120 reports
• Semaglutide (Wegovy and Ozempic): 59 reports
• Liraglutide (Saxenda): 37 reports

It is important to remember that Yellow Card reports record suspected side effects and are not confirmation that the medicine caused the event.

Why Are These Reports Increasing?

Several factors may explain the growing number of reports.

First, prescriptions for GLP-1 medications have increased dramatically over the past few years as more patients become eligible for treatment.

Second, healthcare professionals and patients are now more aware of the importance of reporting suspected side effects.

Finally, increased use naturally results in a larger number of reported adverse events, even if the overall safety profile remains favorable.

The MHRA continues to monitor these reports alongside clinical studies and international safety data.

Common Side Effects of GLP-1 Weight Loss Medications

Most people using GLP-1 medications experience mild or temporary gastrointestinal symptoms.

Common side effects include:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Reduced appetite
• Abdominal discomfort

These symptoms often improve as the body adjusts to treatment.

Healthcare providers typically recommend gradually increasing the dose to reduce the likelihood of side effects.

Serious Complications Under Investigation

Although uncommon, regulators continue to monitor reports involving more serious medical conditions.

These include:

• Acute pancreatitis
• Gallbladder disease
• Severe dehydration
• Kidney injury
• Gastroparesis, sometimes called delayed stomach emptying
• Intestinal obstruction
• Rare bowel complications

Medical experts advise that severe or persistent abdominal pain should always be assessed urgently, particularly if it is accompanied by vomiting, fever, or signs of dehydration.

Case Highlights Ongoing Monitoring

Recent media coverage has highlighted the death of a 73-year-old woman following an increase in her prescribed Mounjaro dose.

According to reports from an inquest, the woman died from faecal peritonitis after a bowel perforation, with experts discussing whether slowed bowel movement associated with GLP-1 medicines could have contributed.

An earlier case involving Scottish nurse Susan McGowan also attracted attention after prescribed tirzepatide was listed as a contributing factor on her death certificate alongside pancreatitis, septic shock, and multiple organ failure.

These individual cases continue to be examined through legal and medical review processes.

What Is the MHRA Yellow Card Scheme?

The Yellow Card Scheme is the UK's official system for collecting reports of suspected adverse drug reactions.

Anyone can submit a report, including:

• Doctors
• Pharmacists
• Nurses
• Patients
• Caregivers
• Pharmaceutical companies

The purpose of the system is to detect potential safety signals that may require further scientific investigation.

Importantly, a Yellow Card report does not establish that a medicine caused the reported event. Many reports involve patients with multiple health conditions or who are taking several medications simultaneously.

Benefits Still Outweigh the Risks for Many Patients

Despite ongoing safety monitoring, UK regulators continue to state that the benefits of GLP-1 medicines outweigh their known risks when used according to approved prescribing guidelines.

Clinical trials have shown these medicines can help patients lose 15 to 20 percent or more of their body weight while improving blood sugar control and reducing obesity-related complications.

For many people living with obesity, these benefits may substantially reduce long-term health risks including heart disease, stroke, and type 2 diabetes.

How Patients Can Use These Medicines Safely

Anyone prescribed Mounjaro, Wegovy, Ozempic, or Saxenda should:

• Follow the prescribed dose schedule
• Never increase doses without medical advice
• Stay hydrated
• Report persistent vomiting or severe abdominal pain immediately
• Attend regular follow-up appointments
• Purchase medication only through legitimate healthcare providers

Patients experiencing concerning symptoms should seek prompt medical assessment rather than discontinuing treatment without professional guidance.

Final Thoughts

The latest MHRA safety data highlights the importance of continued monitoring as GLP-1 medications become increasingly common across the UK.

While reports of 216 suspected deaths and 18,000 serious adverse reactions deserve careful attention, they should be interpreted within the broader context of millions of prescriptions issued and the purpose of the Yellow Card reporting system.

For most eligible patients, healthcare professionals continue to consider these medications an effective treatment option when prescribed appropriately and monitored carefully.

Sources

• UK Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme
• MHRA Drug Safety Monitoring Reports
• National Institute for Health and Care Excellence (NICE) guidance on obesity treatment
• Eli Lilly (Mounjaro prescribing information)
• Novo Nordisk (Wegovy, Ozempic, and Saxenda prescribing information)

Disclaimer: This article is for informational purposes only and should not be considered medical advice. The adverse event figures discussed are based on suspected reports submitted to the MHRA Yellow Card Scheme and do not establish that the medications caused the reported outcomes. Patients should consult a qualified healthcare professional before starting, stopping, or changing any prescribed medication.